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ABSTRACT  
   
Throughout time, compounds from natural sources have provided humans 
with medicines, and recently become the structural inspiration for semisynthetic 
drugs.  One arena that has benefited greatly from the use of these natural products 
is the discovery of novel antibacterial agents.  Methicillin-resistant Staphylcoccus 
aureus (MRSA) continues to plague the United States as well as throughout the 
world, at least in part because of increasing antibiotic resistance.  Therefore, 
scientists continue to scour natural products as potential leads, either directly or 
indirectly, for antibiotics to treat MRSA. 
The structure of the indole sesquiterpene, polyalthenol, was discovered in 
1976 and recent work shows a 4µg/mL minimum inhibitory concentration (MIC) 
against a variety of strains of MRSA.  Given the unique framework of this natural 
product and its biological activity against MRSA, the total synthesis becomes the 
next logical step.  Presently a racemic synthesis has successfully afforded an 
indole ketone with the correct relative stereochemistry of polyalthenol, however, 
the completion of the total synthesis of polyalthenol presents several challenges.  
Herein, the work towards the synthesis is described in addition to the proposed 
completion of the synthesis.  
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Chapter 1 
Natural Products Chemistry 
1.1 The History of Natural Products 
 Throughout history humans have relied on nature to meet their most basic 
needs, including but not limited to, the production of food, shelter and 
transportation. The treatment of diseases and other ailments with naturally derived 
medicines is no exception.
1
  The use of these natural sources, most often marine 
organisms, plants, fungus, and recently prokaryotes, for the production of 
medicines represents one facet in the field natural products chemistry.  Classical 
natural products-based drug discovery involves the extraction, isolation, 
purification, and characterization of compounds from their natural sources.
2
  It is 
important to keep in mind that these natural products are just that, products of 
nature, and not in themselves drugs. Only through biological assays, used to 
determine activity against a variety of human infections, are the compounds 
identified as leads, which become candidates for future drug development. When 
compounds are deemed biologically active, organic chemists utilize synthetic 
methodologies to produce large quantities of the compound in a laboratory, for 
further research and the production of lead compounds and analogues.  
Throughout time, humankind has discovered and made use of an enormous range 
of natural compounds
3
; to date the Dictionary of Natural Products (DNP) has 
over 243,000 entries.
4
  
 Based solely on empirical observations and folklore, natural product 
extracts were the first, and for a long time, the only medicines available to 
  2 
mankind.
5
  The oldest medicinal texts, written on clay tablets in cuneiform, are 
from Mesopotamia circa 2600 BC.  They describe approximately 1000 plant 
derived substances, such as Cedrus species (cedar) and Cupressus sempevirens 
(cypress), Glycyrrhiza glabra (licorice), Commiphora species (myrrh), and 
Papaver somniferum (poppy juice), all of which are still in use today for the 
treatment of ailments ranging from coughs to parasitic infection to inflammation.  
Traditional Chinese medicine is also well known for its extensive use of natural 
products, the first record of the Chinese Materia Medica dates from about 1100 
BC.
1
  The Indian Ayurveda (science of life), which covers disease, therapeutics, 
and pharmacy, has a vast literature in Sanskrit as well as other Indian languages 
and dates back to approximately 900 BC.  The Charaka Samhita is the first 
recorded writing fully devoted to the concepts and practices of Ayurveda and lists 
341 plants and plant products used for medicinal purposes.
6
  In the ancient 
Western world, the Greeks contributed to the rational development of the use of 
herbal drugs.  The History of Plants from 300 BCE dealt with the medicinal 
properties of herbs and around 100 CE Dioscorides, a Greek physician, recorded 
the collection, storage and use of medicinal herbs.
7
  During the Dark and Middle 
Ages (401 CE – 1499 CE) the remnants of this Western knowledge were 
preserved in countries such as England, Ireland, France and Germany and in the 
early eighth century it was the Arabs that contributed much to pharmacy and 
medicine by publishing the Canon Medicinae.  The London Pharmacopoeia, 
published in 1618, was the first formal compilation of these, as well as, many 
other ancient medicinal practices.   
  3 
What followed in the early 1800’s was the idea that the isolation of active 
components of commonly used plants and herbs such as strychnine, atropine and 
colchicines could be traced back to ‘pure’ compounds.1  Modern chemistry 
provided the tools to purify a variety of compounds and to determine their 
structures.  These advancements resulted in what became both the first pure 
naturally derived medicine and the first to be commercialized, morphine (Figure 
1.1).  Morphine, which is produced by cut seed pods of the poppy, Papaver 
somniferum, was first distributed by E. Merck in 1826.
8
   
 
 
 
Figure 1.1. (A) Papaver somniferum; Opium Poppy. Jo-Ann Ordano © California 
Academy of Sciences; (B) Chemical structure of morphine. 
 
The predecessor of aspirin, salicylic acid, was known at least from the 
fifth century BC when it was extracted by Hippocrates from the bark of the 
willow tree.  Synthetic salicylates were produced on large scale by the Bayer 
Company in 1874 but it was not until twenty years later that Bayer produced 
aspirin, which is generally thought to be the first semi-synthetic pure drug based 
on a natural product.
9
  These breakthroughs, as well as many others, initiated an 
era in which drugs from plants could be purified, studied, and administered in 
 
A B 
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precise dosages that did not depend on the original source.
10
  The discovery of 
penicillin, derived from the mold Penicillium notatum, by Alexander Fleming in 
1928 and its development into a medicine provided the foundation for the 
development of natural products as the cornerstone of new drug discovery in the 
20
th
 century and beyond.
11 
1.2 Natural Products to the Pharmacy 
The examples of natural products turned successful pharmaceuticals are 
plentiful, and in our current view we should see natural products as both a 
fundamental source of new chemical diversity and an integral component of 
today’s pharmaceutical industry.12  We do not have to look much further than the 
examples of morphine from poppies, cardiotonic digitalis glycosides from 
foxglove, and penicillins from fungi to see the importance of natural products in 
the pipeline for investigational drugs.  The continued influence of natural products 
as leads to or sources of drugs over the years 1981-2006 is evident in the work by 
Newman and Cragg as shown in Figures 1.2 and 1.3.
13-15
     
 
Figure 1.2. Source of small molecule drugs, 1981-2006: major categories, N = 
983 (in percentages). Major categories are as follows: “N”, natural product; 
“ND”, derived from a natural product and usually a semi-synthetic modification; 
“S”, totally synthetic drug often found by a random screening/modification of an 
existing agent; “S*”, made by total synthesis, but the pharmacophore is/was from 
a natural product.
15 
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Figure 1.3. Source of small molecule drugs, 1981-2006: all categories, N = 983 
(in percentages). Major categories are as follows: “N”, natural product; “ND”, 
derived from a natural product and usually a semi-synthetic modification; “S”, 
totally synthetic drug often found by a random screening/modification of an 
existing agent; “S*”, made by total synthesis, but the pharmacophore is/was from 
a natural product. The subcategory is as follows: “NM”, natural product mimic.15 
Although estimates vary, mostly depending on the definition of a natural 
product-derived drug, it is acceptable to say that somewhere between 25% and 
50% of currently marketed drugs owe their origins to natural products.
16
  Natural 
products are typically classified as such when the compound is either extracted 
from the source or the structure is replicated using synthetic methods.  Natural 
product-derived drugs are derivatives of the natural product with synthetic 
modifications, typically to increase biological activity and/or bioavailability.  
Additionally, compounds may be considered a natural product despite the use of 
totally synthetic methods when the pharmacophore was inspired by a natural 
product.  The amount of totally synthetic drugs, often found from random 
screening, is very limited.  In Figure 1.3 this represents just 5.3% of small 
molecule drugs from 1981 to 2006. 
The percentage of natural product drugs may be even higher for certain 
classes, specifically anticancer and anti-infective agents.  It is believed that as 
much as two-thirds of these agents are from natural sources.
17
  In the United 
  6 
States it is estimated that over 50% of the most-prescribed drugs were either a 
natural product or a natural product was used as a template in the synthesis and 
design of the agent.
1
  Between 1985 and 2006 almost half of new drugs 
introduced into the market were natural products or their derivatives and they 
represented over $40 billion in sales.
18
    
Despite the successes in natural products chemistry, the role of natural 
products in drug discovery has seen many changes over the past three decades 
with a noticeable fall off in the early 1990’s (Fig. 1.4).10  This decline is mainly 
due to the launch of high-throughput screening (HTS) of combinatorial chemistry 
libraries followed by optimization of hits, thought to be the new frontier in drug 
discovery.  The expected surge in productivity never materialized and the number 
of New Chemical Entities (NCEs) hit a 24-year low of 25 in 2004.
14
  The switch 
 
Figure 1.4. Drugs approved in the United States from 1981 – 2007.10 
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away from natural products to HTS combinatorial chemistry might have led to the 
current scarcity of new drug candidates in the development pipeline.
3 
 Over the 
past 20 years there has been only a handful of FDA-approved drug resulting from 
HTS, well-known examples include the kinase inhibitors sunitinib for renal 
carcinoma and sorafenib (Nexavar) both approved in 2005.
19-20
  Thus natural 
product-based drugs (parent compounds, derivatives, analogues, and mimics) are 
still the major entities among the FDA-approved drugs (57.7% of all drugs).
2  
The 
attractiveness of natural products will continue because they are ideal as sources 
of novel drug leads and the inspiration for the synthesis of non-natural molecules.    
Thirteen natural product-derived drugs were approved in the United States 
between 2005 and 2007 (Table 1.1).
21
  Of those, five of them represented the first 
members of new classes: the peptides exenatide and zironotide, and the small 
molecules ixabepilone, retapamulin and trabectedin.
22 
Table 1.1 NP-derived drugs launched since 2005 by year with reference to their 
lead compound, classification and therapeutic area.
21 
 
Year Generic Name (trade name) Lead Compound Classification Disease area 
2005 dronabinol/ cannabidol (Sativex®) dronabinol/ 
cannabidol 
NPs pain 
2005 fumagillin (Flisint®) fumagillin NP antiparasitic 
2005 doripenem (Finibax®/Doribax ™) thienamycin NP-D antibacterial 
2005 tigecycline (Tygacil®) tetracycline SS* NP antibacterial 
2005 ziconotide (Prialt®) ziconotide NP pain 
2005 zotarolimus (Endeavor™ stent) sirolimus SS* NP cardiovascular surgery 
2006 anidulafungin (Eraxis™/Ecalta™) echinocandin SS* NP antifungal 
2006 exenatide (Byetta™) exenatide-4 NP diabetes 
2007 lLisdexamfetamine (Vyvanse™) amphetamine NP-D ADHD 
2007 retapamulin (Altabax™/Altargo™) pleuromutilin SS* NP antibacterial (topical) 
2007 temsirolimus (Torisel™) sirolimus SS* NP oncology 
2007 trabectedin (Yondelis™) trabectedin NP oncology 
2007 ixabepilone (Ixempra™) epothilone B SS* NP oncology 
Classifications: “NP”, natural product; “NP-D”, Natural Product-derived; “SS* NP”, semi-synthetic Natural 
Product. 
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After more than twenty years of research and development, ziconotide, now 
known under the trade name Prialt, was the first marine-derived drug approved by 
the FDA.
 
 This peptide toxin isolated from the cone snail Conus magus was 
approved in 2004 for the treatment of chronic pain following spinal cord injuries 
(Figure 1.5A).
10,23
  Trabectedin, with the trade name Yondelis, from Ecteinascidia 
turbinata (Figure 1.5B) has been approved in Europe since 2007 for the treatment 
of advanced soft-tissue carcinoma and illustrates a significant milestone in the 
development of marine-derived drugs.  Almost four decades after its discovery 
and seventeen years after its structure was elucidated, Ecteinascidin-743 became 
the first marine-derived anticancer drug to reach the market.
23
 
 
 
Figure 1.5. (A) Textile cone snail Conus magus; (B) The Caribbean sea-squirt 
Ecteinascidia turbinata.  Image courtesy of Susanna Lopez-Legentil. 
 
1.3 Antibacterials Inspired by Natural Products 
 The development of new anti-infective drugs is one arena in which natural 
products have dominated.  As previously mentioned, natural products play a 
particularly crucial role in both anticancer and anti-infectious disease drug 
discovery, with approximately 60% and 75% of drug candidates respectively 
A B 
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coming from either natural products or natural product derivatives.
24-25
  Over 
evolutionary time, many organisms, specifically marine eukaryotes, have 
developed a plethora of anti-infective molecules and strategies by which they 
protect themselves against attack.  Given this tendency, it is understandable why 
efforts have been made to identify and characterize antimicrobial factors from 
these organisms.
26
  Since their introduction, in the early part of the last century, 
antibiotics have been considered ‘wonder drugs’ but their popularity and overuse 
have lead to resistance as pathogens have evolved.  To address the need for novel 
and effective antibiotics, and to fight against the continued resistance, 
pharmaceutical companies have recharged their efforts in the development of new 
antibiotics based on natural products. 
 The first powerful antibiotic used widely by civilians was penicillin.  
Following the isolation of penicillin from the fungi Penicillium notatum in the 
early 1940’s, the number of penicillin-based molecules that have been produced 
by semi- and total synthesis to date is well over 15,000.
7
  The ring-expanded 
version of  penicillin, cephalosporin C, from the species Cephalosporium
 
was 
reported in 1948 and its structure was determined thirteen years later.
27-28
  The 
penicillin core served as the template for thousands of cephalosporins and in 1970 
the first orally-active molecule, cephalexin, was introduced.  Since that time, 
numerous cephalosporins including: cefalotin, cefuroxime, ceftazidime, and 
cefepime, have been synthesized with the aim at producing molecules that are 
more resistant to β-lactamases.29  Biapenem 1 (Omegacin®) and ertapenem 2 
(Invanz
®
) both introduced in 2002 and doripenem 3 (Finibax
®
) introduced in 2005 
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are carbapenem antibiotics (part of the β-lactam family).  These three carbapenem 
drugs are produced synthetically but their lead structure is the natural product 
thienamycin.
7,14
  The mechanism of action of these three drugs, like other β-
lactam antibiotics, is the inhibition of bacterial cell wall synthesis.
30-31
  Yet 
another class of natural product-inspired antibiotics is that of the tetracyclines, 
discovered in the 1940’s.  Since the discovery of chlortetracycline in 194532 from 
Streptomyces aureofaciens, other tetracyclines have followed, some naturally 
occurring, such as tetracycline from S. aureofaciens and others, such as 
doxycycline and minocycline, which are semisynthetic products.
33
  The naturally 
occurring tetracycline pharmacophore still serves a vital role in the development 
of tetracycline analogues.  More recently, Wyeth Pharmaceuticals received 
approval from the FDA to market Tygacil
®
 (tigecycline 4) which is the 9-t-
butylglycylamido derivative of minocycline.
34
  Tigecycline specifically inhibits 
protein synthesis by binding to the 30S and 70S ribosome subunits, showing 5-
fold and 100-fold-greater affinity than minocycline and tetracycline, 
respectively.
35
    Erythromycin, a product of Saccharopolyspora erythraea, was 
first reported in 1949 and represents the most classical example of a macrolide 
antibiotic.  Telithromycin 5 (Ketek
™
), a semi-synthetic derivative of erythromycin 
A, received FDA approval in 2004 and is the first ketolide antimicrobial.
36-37
  
Telithromycin is a very effective inhibitor of the translational function at the level 
of the 50S ribosomal unit and additionally, like many other carbamate keolides, is 
able to inhibit the formation of the 30S ribosomal unit.  This dual mechanism of 
action may reinforce the bactericidal nature of this compound and explains its 
  11 
increased activity over other members of the macrolide class.
38 
 Another recently 
approved drug related to the macrolides is daptomycin 6 (Cubicin
®
), a cyclic 
lipopeptide derived from Streptomyces roseosporus, that works by disrupting 
multiple aspects of bacterial membrane function including the disruption of 
membrane potential and amino acid transport, inhibition of lipoteichoic acid 
synthesis and inhibition of peptidoglycan synthesis.
39 
 Daptomycin received US 
approval in 2003 for use in the treatment of complicated skin and skin structure 
infections.
40
  Figure 1.6 shows the six new natural product-derived antibacterials 
launched between  2000 and 2008. 
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Figure 1.6. Antibacterials: Natural Product-derived drugs launched between 2000 
and 2008.   
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Chapter 2 
 
Understanding Methicillin-Resistant Staphylococcus aureus 
2.1 Methicillin-Resistant Staphylococcus aureus (MRSA) 
 Staphylococcus aureus was first discovered in the late 1880’s when 
Alexander Ogston described what he called ‘staphylococcal disease’ based on the 
organisms role in sepsis and abscess formation.
41
  S. aureus is classified as a 
gram-positive cocci and is a member of the Micrococcaceae family
42
 (Figure 
2.1).
43  
The bacteria permanently colonize the moist squamous epithelium of the 
nares in 20% of the population and is transiently associated with another 60%, 
occasionally causing infection.
44-45
  Described as one of the most dangerous 
human bacterial pathogens, S. aureus causes a variety of infections and toxinoses; 
most commonly skin and soft tissue infections (SSTI’s), bacteremia or sepsis, 
pneumonia, endocarditis, and osteomyelitis.  
 
 
Figure 2.1. Microscopic structure of S. aureus.  Courtesy of the Centers for 
Disease Control and Prevention (CDC). Images 11159, 11157, and 10045 
respectively. 
 
The common use of penicillin and other β-lactam antimicrobial drugs in 
the 1940’s, although considerably improving the management of staphylococcal 
infections, contributed to the emergence of methicillin-resistant Staphylococcus 
aureus (MRSA).
46 
  The origin of the first MRSA strain resulted from the 
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staphylococcal cassette chromosome mec (SCCmec), with a β-lactam resistant 
gene mecA, being integrated into the chromosome of a S. aureus susceptible 
strain.
47-48  
 Only a few short years after the introduction of the methicillin 
antibiotic, the appearance of these S. aureus strains, that were resistant to 
methicillin (Celbenin), were reported in the United Kingdom.
49
  Although the 
United Kingdom was the first to report methicillin resistant strains in 1961, many 
other regions followed, including the first case of MRSA in Sydney, Australia in 
1965 and the first hospital outbreak in the United States at Boston City Hospital in 
1968.
50
  Up until the mid-1990’s our understanding of MRSA was limited mainly 
to information obtained from health care settings, mostly because it was rare that 
MRSA would infect otherwise healthy individuals.  However, since then there has 
been an explosion in the number of infections reported in low-risk populations.
 
The terms healthcare associated MRSA (HA-MRSA) and community-
associated MRSA (CA-MRSA) are typically used to describe microbiological and 
genetic differences as well as epidemiological, clinical, and therapeutic 
differences in the infections that they cause (Table 2.1).
51-52
  Healthcare 
associated strains are generally found to be resistant to a broader spectrum of 
antimicrobial agents and/or classes and are often multidrug-resistant (MDR-
MRSA), on the other hand CA-MRSA are resistant to a limited number of 
antibacterial agents, most often clindamycin and the tetracyclines.
53
  Community 
associated strains historically have the following traits: predominantly from strain 
ST8:USA300 which belongs to the CC8 clonal complex of pulsed-field gel 
electrophoresis (PFGE) type, carry their mutant penicillin-binding protein 2a 
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(PBP2a) on mobile genes classified as SCCmec type IV, and typically possess the 
two genes encoding Panton-Valentine leukocidin (PVL).  In comparison, HA-
MRSA is typically characterized by a more heterogeneous PFGE type, carry 
SCCmec type I, II and III, and often lack PVL genes.
46,53-54
  Since about 2003, the 
ability to differentiate between CA-MRSA and HA-MRSA strains have become 
increasingly more difficult.  Occasionally, HA-MRSA isolates do circulate in the 
community and many reports have demonstrated that CA-MRSA, particularly the 
most dominate of strain USA300, now cause nosocomial MRSA outbreaks and 
infections among patients suffering from chronic illnesses.
51
 In 2004-2005, CA-
MRSA accounted for more than 80% of all MRSA infections; this statistic 
highlights the changing paradigm of MRSA as the prevalence of CA-MRSA 
surpasses that in the hospitals.
55
  
Table 2.1. Common Characteristics of Infection Caused by MRSA
51-52
  
 
Characteristic HA-MRSA CA-MRSA 
Year of Discovery 1961 1980’s 
Population at Risk Patients having previous 
hospitalizations, surgery, 
residence in long-term care 
facilities, dialysis, permanent 
indwelling catheters, ICU 
Children, homeless, men who 
have sex with men, athletes, 
military recruits, jail inmates, 
native Americans, Pacific 
Islanders, adult emergency 
department patients 
Main Clinical Symptoms Bacteremia, HAP, VAP, catheter- 
and prosthetic-related infections 
SSTI, necrotizing CAP, 
bacteremia, osteomyelitis 
Antibiotic Resistance Profile MDR; including β-lactams, 
macrolides, TMP-SMX, 
lincosamides, tetracyclines, 
rifampin, quinolones 
 
Growing resistance to 
glycopeptides  
Resistant to β-lactams. Variable 
susceptibility to macrolides, 
TMP-SMX, tetracyclines, 
lincosamides 
SCCmec type associated with 
strains causing infection 
I, II, and III IV and V 
Expression of PVL Rare Common 
ICU: intensive care unit; HAP: hospital-associated pneumonia; VAP: ventilator-associated pneumonia; 
SSTI: skin and soft tissue infection; CAP: community-associated pneumonia; MDR: multidrug resistant; 
TMP-SMX: trimethoprim-sulfamethoxazole; SCCmec: staphylococcal chromosomal cassette mec; PVL: 
Panton-Valentine leukocidin; PFGE: pulsed-field gel electrophoresis. 
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2.2 Statistics on MRSA  
In the United States it is estimated that each year over 1.5 million 
individuals acquire an infection while hospitalized, resulting in nearly 100,000 
deaths.  A great number of these infections are caused by antimicrobial resistant 
organisms, and MRSA ranks among the most prevalent pathogens in hospitals 
worldwide.
56
  According to the CDCs Active Bacterial Core Surveillance (ABCs) 
Report in 2009, approximately 90,000 cases of invasive MRSA were estimated 
with around 14,000 mortalities reported.
57
  Although the rates of infection are 
declining, the CDC still estimates that the number of CA-MRSA and HA-MRSA 
infections and mortalities in the United States in 2010 will reach 82,000 and 
almost 12,000 respectively, based on the most current ABCs Report (Table 2.2).
58  
Although MRSA continues to be a burden both nationally and internationally, the 
lack of international standards makes the interpretation of data difficult and 
impedes on prevention efforts.
59
    
Table 2.2. National Estimates and Adjusted Incidence Rates of Invasive MRSA 
Infections and Mortality among Cases
58 
Epidemiological Category Estimated Cases of Infection Estimated Rates of Mortality 
 Estimated 
 No. 
Incidence Rate 
(Confidence Interval)a 
Estimated 
No. 
Incidence Rate 
(Confidence Interval)a 
CA 13,799 4.47 (4.17-4.79) 665 0.22 (0.14-0.36) 
HCA 67,034 21.76 (21.08-22.46) 10,202 3.31 (3.04-3.59) 
HCA-HO 15,744 5.10 (4.78-5.44) 3,507 1.14 (0.98-1.31) 
HCA-HACO 51,290 16.61 (16.02-17.23) 6,695 2.17 (1.95-2.40) 
Overall 82,042 26.57 (25.82-27.34) 11,478 3.737 (3.44-4.02) 
a National estimates and Incidence (no. per 100,000 population per year) are adjusted for age, race, and 
gender using 2010 US Census data. 
CA: community-associated; HCA: healthcare-associated; HO: hospital-onset; HACO: healthcare-
associated community-onset. 
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2.3 Current Treatments for MRSA and Expected Need for New Antibiotics 
 Before the introduction of antibiotics, the mortality rate of staphylococcal 
bacteremia was greater than 70%, that was of course until the widespread use of 
penicillin decreased the rate of mortality by approximately 25%.
60
  This same 
trend continues with the introduction of new antibiotics, initially the rate of 
mortality decrease, but as resistant Staphylococcus aureus develops the drugs 
become less effective and an increase in mortality is seen (Figure 2.2).
61-63
  It is 
not surprising then that clinical isolates resistant to linezolid (ZYVOX
®
), one of 
the newest antibiotics used to treat MRSA, have already been reported.
64
  This 
evolution shines a light on the impact of staphylococcal resistance in the past 60 
years and highlights the continued need for the development of novel antibiotics.  
 
Figure 2.2. Mortality rate of staphylococcal bacteremia over time. MSSA: 
methicillin-susceptible S. aureus;  MRSA: methicillin-resistant S. aureus; VISA: 
vacomycin-intermediate S. aureus.  Image reproduced with permission from 
Oxford Journals, United Kingdom.
61-63 
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Vancomycin  
Vancomycin is a glycopeptides antibiotic isolated in 1956 by scientists at 
Eli Lilly
65
 from the fermentation broth of the actinomycete Amycolatopis 
orientalis, formally Streptomyces orientalis
66
 (Figure 2.3).  It is active against 
Gram-positive cocci, particularly streptococci, staphylococci, and pneumococci 
and its mode of action is inhibition of cell wall synthesis.
67
  The rather large 
vancomycin molecule inhibits cell wall synthesis by interfering with the synthesis 
of the peptidoglycan of bacterial cell walls.
68
  Vancomycin received FDA 
approval in 1958 but its clinical uses were overshadowed by the introductions of 
methicillin, cephalosporins, and linomycins which had wider clinical acceptance.  
Vancomycin was not commonly used until the 1980’s after its purity was 
improved, which alleviated many unwanted side-effects, and drug resistance to 
other antibacterial agents increased.
69 
 
 
Figure 2.3. Amycolatopsis orientalis. Image reproduced with permission from the 
Digital Atlas of Actinomycetes, contributor of this image Y. Gyobu. 
 
What is extremely unique about vancomycin is that, unlike any of the 
other antistaphylococcal antimicrobials, resistance to this agent among S. aureus 
strains was very slow.  Although the emergence of resistance was predicted, as 
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high levels of resistance to vancomycin in enterococci (VRE) were seen in the 
late 1980’s, it took almost 40 years to isolate MRSA with reduced susceptibility 
to vancomycin.
70
  In January 1996, a clinical strain of MRSA labeled Mu3 
(heterogeneously vancomycin-resistant S. aureus) was isolated and 6 months later 
another strain designated Mu50 (vancomycin-resistant S. aureus) was isolated 
from a pediatric patient in Japan.
71-72  
Despite the evolution of vancomycin 
resistant S. aureus, it has been the mainstay for methicillin-resistant isolates and 
remains the drug of choice in severe infections that require intravenous 
antibiotics.  Additionally, vancomycin (Figure 2.4) is typically used to treat 
staphylococcal infections caused by bacteremia, endocarditis, pneumonia, 
cellulitis, and osteomyelitis.
73-74
  Patients unable to tolerate vancomycin have 
been treated with fluoroquinolones, trimethoprim-sulfamethoxazole (TMP-SMX), 
clindamycin, or minocycline, as these drugs have shown efficacy in cases that 
require bactericidal therapy.
42 
 
 
 
Figure 2.4. Chemical Structure of Vancomycin 
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Clindamycin  
 Clindamycin (Figure 2.5) is approved by the FDA for the treatment of 
serious infections caused by S. aureus, although not specifically for the treatment 
of MRSA.  However, it has become widely used for the treatment of SSTI’s, bone 
and joint infections, and has been successfully used for CA-MRSA infections in 
children.
75
  Clindamycin, much like macrolides and other lincosamides, binds to 
the 50S ribosomal subunit which in turn disrupts protein synthesis by interfering 
with the transpeptidation reaction.
76
  Its action may be bacteriostatic or 
bactericidal depending on various factors, including drug concentration, bacterial 
species, and inoculum.
77
  Evidence of the efficacy of clindamycin as the sole 
agent against MRSA strains with macrolide resistance has been shown in the 
United Kingdom, however the risk of emergence of resistance is still warranted, 
as 80% of CA-MRSA strains are reported to be susceptible.
73,78
  Just recently, 
high frequencies of clindamycin resistance in MRSA were reported among the 
predominate USA300 strain in Boston, Massachusetts.
79
  
 
 
Figure 2.5. Chemical Structure of Clindamycin 
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Rifampicin 
Rifampicin (known as rifampin in the United States) is a semisynthetic 
compound derived from Amycolatopsis mediterranei
80 
and has bactericidal 
activity against S. aureus.
75 
 The high level of antibacterial activity of rifampicin 
is based on a specific and unique mechanism of action, the inhibition of DNA-
dependant RNA polymerase to prevent chain elongation.
81
  Rifampicin 
indications include bone and joint infections, SSTI’s, eradication therapy, and 
adjunct treatment of prosthetic infections.
78,82
  Rifampicin (Figure 2.7) has good 
activity against CA-MRSA but should not be used as a monotherapy because of 
the rapid development of resistance, even during single drug administration. 
 
Figure 2.6. Chemical Structure of Rifampicin 
 
Tetracyclines: Doxycycline, Minocycline, Tigecycline 
 The tetracycline family of antibiotics have historically maintained activity 
against a wide spectrum of bacteria, however, because of widespread use 
resistance to this class of antibiotics is now extensive.
83
  The tetracyclines 
specifically inhibit bacterial protein synthesis by preventing the binding of 
aminoacyl tRNA to the ribosomal acceptor (A) site.
84
  The FDA has approved the 
use of doxycycline (Figure 2.9) for the treatment of SSTI’s caused by S. aureus, 
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although not specifically those due to MRSA infections.  In cases of doxycycline 
resistance, minocycline (Figure 2.9) represents an alternative that is available 
orally.
 
 Tigecycline (Tygacil
™
), a glycylcycline and derivative of the tetracyclines, 
received FDA approval for the treatment of SSTI’s and intrabdominal infection in 
2004.
75
  Its activity against MRSA is superior to older agents, in addition 
tigecycline possess a modest Gram-negative spectrum of activity.  As mentioned 
in the previously, tigecycline inhibits protein synthesis by binding to both the 30S 
and 70S ribosomal subunits, showing a 5-fold-greater affinity than minocycline.
35
  
Tigecycline (Figure 2.9)  has also shown efficacy in infections caused by 
glycopeptide/vancomycin-intermediate (G/VISA) S. aureus.
83
 
  
All the 
tetracycline antibiotics are contradicted in children younger than 8.
43 
 
Figure 2.7. Chemical Structures of the Tetracyclines 
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Linezolid 
 
The discovery of linezolid (ZYVOX
®
) is a unique story, mainly because it 
is a representative of the first new structural class of antibacterial agents in over 
35 years, the oxazolidinones.  Prior to the discovery of this novel class the vast 
majority of antibiotics were either natural products or chemically modified 
derivatives of known scaffolds.  In 1987, information out of DuPont revealed that 
a number of oxazolidinone compounds showed potent inhibition of Gram-positive 
bacteria, including MRSA, and most importantly their activity was not affected by 
any known antibiotic resistance mechanism.
85
  Two new agents, DuP 721 (Figure 
2.10) and DuP 105, were identified by DuPont as potential leads, however, the 
group discontinued the oxazolidinone program, presumably because of toxicology 
findings.  Dr. Steven Brickner at the Upjohn Company, in Kalamazoo, Michigan, 
recognized the potential of this class and set a goal of identifying potent, yet safer 
oxazolidinones.  Thousands of analogs were synthesized with the aim of 
identifying the best compound that had both potent in vivo and in vitro 
antibacterial activity, high water solubility, and a good safety profile.
86
  This work 
lead to the discovery of linezolid, which was approved by the FDA in 2000 for 
adults and children for the treatment of SSTI’s and nosocomial pneumonia due to 
MRSA.
75
  Oxazolidinones disrupt bacterial growth by binding to the 50S subunit 
of the bacterial ribosome, preventing it from complexing with the 30S subunit, 
mRNA, initiation factors and formylmethionyl-tRNA.  The overall result is the 
inability of the prokaryote to assemble a functional initiation complex for protein 
synthesis, preventing the translation of the mRNA.
 
 This site of inhibition occurs 
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earlier in the initiation process than other protein synthesis inhibitors, which either 
block polypeptide extension or cause misreading of the mRNA.
87
  Linezolid 
(Figure 2.10) represents the first and only pharmacologically active oxazolidinone 
in clinical use, is the only FDA approved oral medication for MRSA skin 
infections, and is considered to be one of the last lines of defense against MRSA.  
Linezolid has become recognized as an important alternative for infections caused 
by multidrug-resistant (MDR) pathogens, and its use continues to increase 
globally.
88
  Not surprisingly though, the first reports of resistant bacterial strains 
to linezolid started to appear shortly after its clinical introduction.
64
  Although the 
number of resistant strains remains low, there are nonetheless reports of linezolid 
resistance involving a variety of clinical settings.
89
 
 
Figure 2.8. Chemical Structures of DuP 721 and Linezolid (ZYVOX
®
) 
Daptomycin  
 Much like linezolid, daptomycin represents the first antibacterial agent in 
a new class of antibiotics known as lipopeptides.  Initially developed by Eli Lilly 
in the early 1980’s, but not FDA approved until 2003 after being purchased by 
Cubist Pharmaceuticals
90
, daptomycin is a naturally occurring cyclic lipopeptide 
that is a fermentation byproduct of Streptomyces roseosporus.
74
  The FDA 
originally approved daptomycin for the treatment of complicated skin and skin-
structure infections (cSSSI’s), three years later in 2006, it gained additional 
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approval for the treatment of blood stream infections and endocarditis caused by 
methicillin-sensitive S. aureus (MSSA) and MRSA.
91
  The primary mechanism of 
action involves the disruption of bacterial membrane function.
92
  The mechanism 
is distinct from previous classes of antibiotics that inhibit bacterial cell wall 
biosynthesis, bacterial DNA replication, and folate coenzyme biosynthesis.  
Daptomycin (Figure 2.11) should not be used for the treatment of respiratory 
infections such as Community-acquired pneumonia (CAP) because its activity is 
inhibited by pulmonary surfactant.
75,78, 91 
 Resistance in MRSA has rarely been 
reported, however it should be noted that many of the systems used for reporting 
resistance have yet to incorporate daptomycin into standard panels.
74
     
 
Figure 2.9. Chemical Structure of Daptomycin 
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Telavancin  
 Telavancin (Figure 2.12) is a bactericidal lipoglycopeptide and a 
semisynthetic derivative of vancomycin, related both structurally and 
mechanistically.
74
  It possess a dual mechanism of action, inhibiting 
peptidoglycan synthesis by binding to D-Ala-D-Ala-containing residues of 
peptidoglycan intermediates and also causing membrane depolarization.
93
  
Telavancin, approved in 2009, represents the newest FDA-approved antimicrobial 
agent for SSTI’s in adults.  It exhibits superior in vitro activity compared to 
vancomycin, including rapid bactericidal activity against glycopeptide-susceptible 
organisms as well as glycopeptide-intermediate susceptible and vancomycin-
resistant S. aureus.
94  
Telavancin has a longer half-life than vancomycin which 
allows for daily infusions and simplifies the intravenous regimen for those 
patients who are being discharged or receive long-term outpatient therapy.
74
  
 
Figure 2.10. Chemical Structure of Telavancin 
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Despite our best efforts, and the introduction of numerous antibiotics to 
treat MRSA infections over the last nine decades (Figure 2.11), none of these 
drugs fully addresses the problem of antibiotic resistance.
82
  As the inevitable 
development of resistant bacteria erodes the utility of today’s antibiotics, 
scientists are left with the unending task of discovering and developing novel 
antibiotics, in particular those with new mechanisms of action. 
 
 
 
 
 
 
Figure 2.11. The Introduction of New Antibiotic Classes and the Emergence of 
Resistance (1925-2010). 
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Chapter 3 
 
Polyalthenol 
3.1 Discovery, Structure and Biological Activity 
The genus Polyalthia (Annonaceae) encompasses a variety of species, 
including Polyalthia suaveolens and Polyalthia oliveri (Figure 3.1)
95-96
, which are 
known to contain compounds with medicinal properties.  P. suaveolens is a small 
tree from the tropical forest zone of West Africa and decoctions of its bark have 
been used in the treatment of blackwater fever and stomach disorders.
97
 
Additionally, the triterpene polycarpol from P. suaveolens has shown inhibitory 
activities on the vitality of adult male worms of Onchocerca gutturosa and is 
considered a promising naturally occurring filaricide.
98
  In earlier papers it was 
reported that both polycarpol and polyalthenol were found in P. oliveri,
97,99
 
however it is believed that polycarpol is present in both P. suaveolens and P. 
oliveri.  Yet another species, Polyalthia lateriflora is used as an antibacterial in 
Malaysia.
100
 
 Figure 3.1. (A) Polyalthia oliveri Engl. (B) African Annonaceae Polyalthia  
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The genus Greenwayodendron has been split off from the genus 
Polyalthia
101
 and there are now two species of Greenwayodendron (G. oliveri and 
G. suaveolens), both of which are commonly found in tropical Africa.
102-103
  Both 
Polyalthia and Greenwayodendron are known to possess indole sesquiterpenes, 
however in contrast to Polyalthia, Greenwayodendron has not been widely 
studied.
104   
The indole sesquiterpene alkaloid, polyalthenol, from the roots of the 
West-African plant Greenwayodendron (Polyalthia) oliveri was first reported in 
1976.
105
  The majority of indole sesquiterpenes, such as polyalthenol 1, have been 
reported from plants and indole diterpenes, such as paxilline, have been reported 
from fungi.  Recently the first indole sesquiterpenes, oridamycin A and 
oridamycin B, have been isolated from bacteria.  These novel indole 
sesquiterpenes are the first described from a prokaryotic source.
106
  
Leboeuf et al. was able to utilize 
1
H-NMR and 
13
C-NMR to confirm the 
gross structure of polyalthenol which allowed for the determination of the relative 
stereochemistry.
105
  However, because the structural assignment was based on 
biogenetic grounds, specifically by analogy to a known sesquiterpene skeleton, 
there remained twenty-two possible structures not excluded using the data 
presented by LeBoeuf et al.
107
  Of these possible structures, another eleven were 
deemed unlikely due to bicyclic ring systems with an exocyclic double bond and 
bicyclic ring systems bearing a double bond at a bridgehead.  The latter is 
energetically less favorable because it violates Bredt’s Rule.108  The relative 
configuration outlined in 2010 by Williams et al. shows the close relationship 
between the structure of polyalthenol 1 and another indole sesquiterpene 
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pentacyclindole 2, the latter most likely being the result of cyclization of C-2 and 
C-17 of polyalthenol (Figure 3.2).
109 
Despite a known relative structure for almost four decades, the biological 
activity of polyalthenol 1 and a group of structurally related indole sesquiterpene 
alkaloids from the genus Greenwayodendron was not investigated until 2010, 
even though the total synthesis and establishment of absolute configuration of at 
least one of the related compounds, suaveolindole 3, had already been reported.
110
 
 
Figure 3.2. Structures of Polyalthenol, Pentacyclindole, and Suaveolindole. 
The biological activity of suaveolindole was reported by Yoo et al. in 
2005, and the natural product shows a minimum inhibitory concentration (MIC) 
of 8 µg/mL for staphylococcus aureus, stain ATTC 6538P, and MRSA strain 
ATTC 33591.
104
  The biologically activity of pentacyclindole 2 is similar to 
suaveolindole, however, polyalthenol 1 shows superior antibacterial activity 
against a variety of MRSA stains (Table 3.1).  Additionally, polyalthenol 1 and 
pentacyclindole 2 showed good inhibitory activity, both compounds possessing 
MICs of 4 µg/mL, against MSSA strain ATCC 25923.
98 
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Table 3.1. MIC of Polyalthenol Determined against Clinical Isolates of 
Staphylococcus aureus
98 
 Virulence gene expression MIC (μg/mL) 
isolate PVL ACME bsa Agr 1 2 
cutaneous       
MRSA-105 + + B + 1 1 8 
MRSA-106 + + B + 1 2 8 
MRSA-107 + + B + 1 1 8 
MRSA-108 + - A + 1 2 8 
MRSA-109 + - B + 1 1 8 
MRSA-111 + + B + 1 2 8 
MRSA-148 + + B + 1 2 8 
MRSA-158 + + B + 1 4 8 
MRSA-175 + - B + 1 4 8 
MRSA-295 - - B + 1 4
 
NT
a 
invasive       
MRSA-186 + - A + 1 4 8 
MRSA-194 + + B + 1 2
 
NT
a 
a
 Not tested due to insufficient material. 
 
3.2 Natural Products with Unique Frameworks 
 
 Since its inception in the early 1990’s high-throughput screening (HTS) 
has dominated lead discovery in pharmaceutical research and chemical biology.  
These screens have proven beneficial with regards to traditional drug targets such 
as ligand-gated ion channels and kinases, however, screening libraries of synthetic 
molecules have been problematic for antimicrobial targets.
110
  One unintended 
consequence of this type of screening is a growing bias towards already known 
scaffolds.  Additionally, synthetic organic chemists continue to alter known 
scaffolds or natural product frameworks, trying to improve the pharmacokinetic 
properties of established drugs.  This bias towards the use of known structures is 
one explanation for the lack of diversity among organic compounds.  A recent 
quantitative examination of the CAS registry showed that only 143 frameworks 
accounted for 50% of the over 24 million cyclic organic compounds.
111 
 This lack 
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of structural diversity creates vast opportunities for synthetic organic chemists to 
expand around neglected and novel frameworks to identify lead compounds. 
One of the promising aspects of polyalthenol 1, as well as the other natural 
products isolated from Greenwayodendron, is its unique framework.  Based on 
the 
1
H-NMR data, polyalthenol 1 appears to be structurally related to 
pentacyclindole 2.  A SubScape analysis of the pentacyclindole 2 framework 
indicates that there are only 213 compounds with the same framework at the 
graph level, indicated by connectivity, but only 7 at the node level, indicated by 
connectivity and heteroframework (Figure 3.3).
109
  Of the 213 compounds with 
the same graph framework, only 2 of them appear to be natural products
112
 and 
only 12 were listed as being bioactive in SubScape.  Given the close structural 
relationship between polylathenol 1 and pentacyclindole 2, and the limited 
number of similar structures, these molecules present a potential new scaffold for 
diversity directed at organic synthesis.  In addition to the total synthesis of 
polyalthenol 1, the identification of a novel scaffold will contribute to our body of 
knowledge in the field of synthetic organic chemistry.  
 
 
Figure 3.3. SubScape frameworks for pentacyclindole at graph, node, and bond 
levels.
109 
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3.3 Closely Related Natural Products 
 
Suaveolindole 
 
 The original synthetic strategy towards suaveolindole involved an 
intramolecular Heck reaction followed by a cross-coupling with a protected 
indole.  This route, however, proved not to be viable partially because of 
difficulties introducing the isopropylidene group.  The heart of the new plan 
centered on the stereoconnectivity of C11 – C16 and acquiring the proper relative 
stereochemistry.  Formation of the indole was accomplished by ozonolysis of the 
terminal olefin and subsequent annulation of the aldehyde with 2-iodoaniline.  
All-carbon quaternary stereocenters were efficiently installed through conjugate 
addition of lithium dimethyl cuprate to the enone.  The carbon framework for the 
isopropylidene group, which had previously eluded the group, was installed 
through carbomethoxylation of the enol triflate species.  Treatment of the allylic 
acetate with LiHMDS/TMSCl provided the desired rearrangement and highlights 
an unprecedented use of the Ireland-Claisen reaction.  The resulting carboxylic 
acid was homologated and the protecting group removed to afford synthetic (+)-
suaveolindole (Scheme 3.1).
113 
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Scheme 3.1.
a
 Total Synthesis of Suaveolindole 
 
 
a
Reagents and conditions: (a) 4-bromo-1-butene, Mg, THF; (b) PCC, DCM, (47% 
from 12); (c) O3, MeOH, Me2S, (88%); (d) 2-iodoaniline, Pd(OAc)2 (5 mole %), 
DABCO, DMF, (68%); (e) TsCl, TBAB, aq. NaOH/benzene, (91%); (f) i) CuI, 
MeLi; ii) PhNTf2, Et2O/THF; (g) CO, Pd(PPh3)4, i-Pr2EtN, MeOH/DMF, (45% 
from 15); (h) MeLi, Et2O, (84%); (i) Ac2O, i-Pr2EtN, DMAP, DCM, (83%); (j) 
LiHMDS, TMSCl, THF, -78ºC, (56%); (k) i) oxalyl chloride, DMF (cat.), DCM; 
ii) CH2N2, i-Pr2EtN, THF, (62%); (l) CF3CO2Ag, Et3N, THF/H2O, (74%); (m) 
naphthalene, Na, DMF, (94%). 
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Chapter 4 
 
Towards the Synthesis of Polyalthenol 
4.1 Introduction 
 As discussed in previous chapters natural products have in the past and 
continue to have an influence on the pharmaceutical industry, providing sources 
of new chemical diversity. Historically, plants have provided us with a variety 
anti-infective agents as well as a number of important antibacterial agents such as 
the alkaloids quinine, emetine and berberine.
114
  In light of this information, along 
with the growing concern over MRSA infections, it is of no surprise that scientists 
continue to look at natural product sources as new leads for antibacterials.  A 
number of compounds isolated from the roots of Greenwayodendron suaveolens 
demonstrate activity against clinical isolates of MRSA.  One of the most 
promising of these compounds, polyalthenol, shows good inhibitory activity 
exhibiting a MIC90 value of 4 μg/mL.
109 
  
Completing a total synthesis of polyalthenol will be significant given the 
continual need for new antibiotics to treat MRSA and the encouraging 
preliminary data on the biological activity of this natural product.  The 
retrosynthetic analysis (Figure 4.1) of polyalthenol 1 is envisioned to establish 
ketone 4 as the initial target structure, with the insertion of the methyl groups by 
first, an asymmetric conjugate addition followed by a trans addition, to enone 5.  
Enone 5 can be prepared using known chemistry outlined by Baraldi et al.
3
 and 
further analysis of 5 yields the commercially available starting materials 
cyclohexenone 6 and 1H-indole-3-carboxaldehyde 7.
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Figure 4.1. Retrosynthesis of Polyalthenol 
4.2 Results and Discussion  
The initials steps in the synthesis involve the formation of the two 
subunits, bicyclic ketone 8 and indole bromide 11, necessary for the coupling 
reaction and subsequent alkylation (Figure 4.2).   
 
Figure 4.2. Retrosynthesis of Alkylation Reaction   
The first ring of the indole sesquiterpene alkaloid, polyalthenol 1, came 
from the commercially available starting material cyclohexenone 6.  Sodium 
methoxide was generated in situ and provide the base necessary for the base-
catalyzed addition of methyl thioglycolate to cyclohexenone 6 (Scheme 4.1).  The 
initial product of the Michael addition is the enolate anion which undergoes a 
spontaneous cyclization with loss of methoxide to afford the bicyclic ketone 8.  
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Known spectroscopic data indicates that the bicyclic ketone 8 is highly enolized 
in CDCl3 and is best represented as the equilibrium mixture of keto-enol 
tautomers.
116
  The present 
1
H-NMR data indicates the presence of the enolized 
structures (Appendix A).  The 47 % yield of the bicyclic ketone 8 was comparable 
to previously reported yields for this reaction. 
Scheme 4.1.
a
 Synthesis of Bicyclic Ketone 
 
 
a
Reagents and conditions: (a) HSCH2CO2CH3, NaOCH3, MeOH, reflux, 47% 
 
The synthesis proceeded in order to obtain the second subunit, indole 
bromide 11, necessary for the coupling alkylation reaction (Scheme 4.2). The 
nitrogen of commercially available starting material 1H-indole-3-carboxaldehyde 
7 was Boc protected using Boc anyhydride in benzene-water and 
tetrabutylammonium iodide as a phase transfer catalyst.  The 90 % yield of the 
crude Boc protected indole aldehyde 9 was higher than previously reported yields 
for this reaction
117
 because of the omission of purification prior to moving 
forward with the synthesis.  Tetrabutylammonium iodide was used in place of the 
prescribed tetrabutylammonium bromide because it was on hand.  The crude Boc 
protected indole aldehyde 9 was reduced using sodium borohydride in ethanol to 
afford Boc protected indole alcohol 10.  This reaction proceeds rather quickly and 
was monitored by Thin Layer Chromatography (TLC).  At the completion of the 
reaction, determined by TLC, hydrogen gas was still being liberated and therefore 
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it was necessary to quench any unreacted sodium borohydride with 1.0M NaOH.  
The final reaction to complete the alkylation coupling partner is the conversion of 
the hydroxyl group to a bromide.  This reaction was initially attempted using N-
bromosuccinimide (NBS) as the source of bromide; however, the literature 
procedure
118
 required stirring at -40 ºC for 12 h and satisfactory yields were not 
accomplished even after the addition of higher equivalences of both NBS and 
triphenyl phosphine (PPh3).  Using carbon tetrabromide (CBr4) as the bromide 
source allowed the reaction to proceed much faster with higher yields and at room 
temperature (RT).  The Appel reaction proceeds by activation of PPh3 with CBr4 
to form the phosphonium salt, followed by attack of the alcohol oxygen at 
phosphorus which displaces the bromide ion.
119
  Additionally, deprotonation of 
the alcohol can occur, forming bromoform, and this may facilitate the attack at the 
phosphorus.  The oxygen is transformed into a good leaving group and an SN2 
displacement by the bromide takes place. The resulting indole bromide 11 was 
rapidly filtered through silica powder to minimize decomposition on silica gel and 
to remove any triphenylphosphine oxide from the reaction.  The overall yield for 
the three steps was 65%.  
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Scheme 4.2.
a
 Synthesis of Boc Protected Indole Bromide 
 
a
Reagents and conditions: (a) NaOH, Boc2O, NBu4
+
 I
-
, benzene, H2O, 90%; (b) 
NaBH4, EtOH, 99%; (c) CBr4, PPh3, CH2Cl2, 73% 
 
The enone 5 that is required for the alkylation reaction is prepared by 
treating the bicyclic ketone 8 with potassium carbonate (K2CO3), followed by 
addition of the indole bromide 11 (Scheme 4.3).  The alkylation reaction with the 
reactive indole bromide 11 proceeded smoothly in the presence of the anhydrous 
K2CO3 in refluxing acetone to afford the alkylated intermediate 12 with a crude 
yield of 89%.  The conditions for the retro-Dieckmann (Figure 4.3) reaction 
proved to be more difficult.     
 
Figure 4.3. Retro-Dieckmann Reaction 
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Originally the reaction was carried out using 5% aqueous sodium 
hydroxide in a two phase, water/diethyl ether, as outlined by Baraldi et al.
115
  
However, the reaction did not proceed to completion and provided very little 
yield, therefore a variety of conditions were evaluated to determine the highest 
yield procedure.  Initially lithium chloride was added to the reaction mixture in 
order to generate lithium hydroxide in situ, which was not immediately available.  
It was determined that the reaction proceeds faster, and with higher yield when 
lithium hydroxide is substituted for sodium hydroxide.  This can be explained by 
the enhanced solvation of the lithium ions in a protic solvent, which is most likely 
due to the ease of hydrogen bonding with the smaller lithium atoms.
120
  After 
determining the increased rate with lithium hydroxide it was necessary to run the 
reaction in a more polar protic solvent system such as methanol:water.  The 
alkylated intermediate 12 is only partially soluble in the methanol:water solution, 
so in order to completely solublize the intermediate, ethyl acetate was added to 
the reaction mixture. The retro-Dieckmann reaction in the presence of lithium 
hydroxide in MeOH:H2O  yielded the enone 5 with 34% overall yield.   
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Scheme 4.3.
a
 Synthesis of Enone 
 
a
Reagents and conditions: (a) K2CO3, acetone, reflux; (b) LiOH, MeOH, EtOAc, 
34% 
 
 The asymmetric conjugate addition (A.C.A.) was initially attempted using 
a chiral ferrocenyl diphosphine catalyst (CFDC) as outlined by Feringa et al.
121 
in 
the presence of copper chloride and the Grignard reagent methyl magnesium 
bromide (Scheme 4.4).  However the results yielded only starting material.  After 
the initial attempts at the enantioselective synthesis were unsuccessful the 
decision was made to proceed through with the racemic synthesis.  
Scheme 4.4.
a
 Attempted Asymmetric Conjugate Addition   
 
 
a
Reagents and conditions: (a) CuCl, CFDC, Et2O, 0.5h, 0ºC 
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The racemic synthesis of ketone 4a and 4b are generated by addition of 
lithium dimethylcuprate prepared from copper iodide and methyl lithium in situ 
(Scheme 4.5).  This procedure circumvents the known problems associated with 
polyalkylation when using Grignard reagents.  Additionally, this reaction takes 
advantage of the higher stereoselectivity and higher yields of 1,4-addition 
products versus addition to the carbonyl (1,2-addition) formed with organocopper 
reagents.
122
  The second methyl group was installed under normal alkylating 
conditions; methyl iodide, diethyl ether, 25ºC, in the presence of lithium chloride.  
Lithium chloride was initially used as a substitute for hexamethylphosphoric 
triamide (HMPA), which is a well-known solvent additive used to coordinate the 
lithium and accelerate the alkylation reaction.
123
  The presence of lithium chloride 
has been shown to accelerate the rate of enolate alkylation reactions in a highly 
diastereoselective manner.
124-125
  Eventually 1-methyl-2-pyrrolidone (NMP) was 
substituted due to the known toxicity of HMPA.  The reaction was very low 
yielding, 20% over two steps, and further work is required to improve on this.       
 
Scheme 4.5.
a
 Synthesis of Ketone 
 
 
a
Reagents and conditions: (a) CuI, MeLi, Et2O, 0ºC, 1h; (b) NMP, MeI, RT, 3h, 
20% 
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The Boc protecting group was removed from the mixture of diastereomers 
4a-4b to afford compounds 4c-4d (Scheme 4.6), which were subsequently sent to 
Arizona State University’s Biodesign Institute, Tempe, AZ, for biological testing 
under the direction of Dr. Shelley Haydel.  Unfortunately the compounds were not 
active, leading to the conclusion that the fourth ring of polyalthenol 1 is required 
for biological activity. 
Scheme 4.6.
a
 Boc Deprotection 
 
a
Reagents and conditions: (a) TFA, CH2Cl2 
 
Initially it was proposed to complete the synthesis of polyalthenol 1 as 
outlined in Scheme 4.7.  The introduction of the carbon chain required for the 
subsequent cyclization would be accomplished by treating ketone 4 with 
bromoacetonitrile.  The resulting ketone will then be treated with the stabilized 
ylide to afford the α,β-unsaturated ester which can be selectively reduced in the 
presence of nitrile with lithium N,N-dimethylaminoborohydride.  The protection 
of the allylic alcohol can be accomplished with a tert-butyl dimethyl silyl group 
(TBS) to give the nitrile 13.  The geminal dimethyl group can then be installed by 
treatment of the nitrile 13 with sodium hydride or lithium diisopropylamine 
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(LDA) and excess methyl iodide.  The conversion of the nitrile to aldehyde 14 can 
then be accomplished using diisobutyl aluminum hydride (DIBAL).  In order to 
complete the intramolecular cyclization the silyl ether protecting group can be 
converted to the allyl bromide 15 by action of fluoride ion then 
triphenylphosphine and carbon tetrabromide. The initial proposal planned to use 
indium in order to catalyze the cyclization and afford the Boc protected 
polyalthenol 16, which can be deprotected with trifluoroacetic acid to complete 
the synthesis of the natural product.   
Scheme 4.7.
a
  Initial Proposed Completion of the Synthesis of Polyalthenol 
 
 
 
a
Reagents and conditions: (a) i) LDA trap with BrCH2CN, ii) Ph3PCHCO2CH3, 
iii) LiMe2NBH3, iv) TBS-Cl; (b) i) NaH, MeI, ii) DIBAL; (c) i) F
-
, ii) PPh3, CBr4; 
(d) metal catalyst 
 
  45 
 As outlined in scheme 4.7, the carbon chain required for the subsequent 
cyclization can be accomplished by treating ketone 4 with bromoacetonitrile.  
This reaction was attempted substituting chloroacetonitrile (Scheme 4.8), however 
the reaction proceeded very slowly.  In order to make the chloroacetonitrile more 
reactive, potassium iodide was added, yet there was no change in the reaction.  
Upon obtaining 
1
H-NMR it was determined that the reaction was unsuccessful, 
and resulted in starting material. 
Scheme 4.8.
a
 Introduction of Carbon Chain 
 
 
a
Reagents and conditions: (a) i) DIA, DME, BuLi, 0ºC, ii) ketone 4 in DME, -
70ºC, iii) ClCH2CN 
 
 Another attempt was made to introduce the carbon chain, this time by 
means of an aldol reaction with acetone.  This step theoretically would also insert 
the geminal dimethyl group present in polyalthenol 1 (Scheme 4.9) in a one pot 
step.  The reaction was monitored by TLC and left overnight.  There appeared to 
be new compounds present before the workup, however after washing with brine 
and extracting with ethyl acetate, the TLC showed only starting material was 
present. 
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Scheme 4.9.
a
 Introduction of Carbon Chain and Geminal Dimethyl Group 
 
a
Reagents and conditions: (a) i) LDA, -78ºC,  ii) ketone 4 in THF,  iii) dry 
acetone, RT, 1.5 h 
After futile attempts at the installation of the carbon chain, it was 
hypothesized that the final ring of polyalthenol 1 could be accomplished using a 
Robinson annulation with mesityl oxide.  This would allow for an overall shorter 
synthesis, as compared to the proposed synthesis in Scheme 4.7, and the 
installation of the geminal dimethyl group in one step.  Previously, Jahnke et al. 
and Dauben et al. have reported successful Robinson annulations using mesityl 
oxide, albeit using harsh conditions.
126-127
  Given the results of their work on the 
Robinson Annulation with hindered enones, it is believed that under high pressure 
the annulation product 19 of ketone 4a and mesityl oxide is possible.  Initial 
attempts at this reaction (Scheme 4.10) in THF:H2O at atmospheric pressure have 
been unsuccessful and further work is required. 
Scheme 4.10.
a
 Synthesis of Ring Core by Robinson Annulation  
 
 
a
Reagents and conditions: (a) mesityl oxide, THF:H2O, 1.0M KOH 
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4.3 Experimental 
General Methods.  DCM refers to dichloromethane, THF to tetrahydrofuran, and 
NMP to N-methylpyrrolidone.  All reagents and solvents were purchased from 
Acros Organics (Fisher Scientific, Pittsburg, PA), Sigma-Aldrich Chemical 
Company (Milwaukee, WI), TCI America (Portland, OR), or Alfa Aesar (Ward 
Hill, WI) and used as received.   All 
1
H-NMR and 
13
C-NMR spectra were 
obtained using Varian Unity 400 MHz with CDCl3 (tetramethylsilane internal 
reference) as solvent unless otherwise noted.  IR spectra were obtained using a 
Jasco FT/IR-4100.   
All reactions were monitored by thin-layer chromatography using 
Analtech silica gel Uniplates and visualized under long-wave and short-wave UV 
radiation.  Vanillin stain (6.0 g vanillin, 1.5 mL conc. H2SO4, 95 mL EtOH) was 
used when compounds were not UV active.  Solvent extracts were dried over 
anhydrous sodium sulfate unless otherwise noted. When appropriate, crude 
reaction products were separated using column chromatography, AnaLogics 
IntelliFlash 280, and silica columns provided by Varian. 
Tetrahydrobenzo[b]thiophene-3,4(2H,3aH)-dione(8).  To 100 mL methanol 
was slowly added sodium solid (2.34 g, 101.8mmol) in pieces at 23.0 ºC over 25 
minutes.  The methanolate solution was then cooled to 0 ºC and treated dropwise 
with a solution of methyl thiolglycolate (10.8 g, 101.8 mmol) dissolved in 20 mL 
methanol.  Next, a solution of cyclohexenone (9.78 g, 101.8 mmol) in 20 mL 
methanol was added dropwise to the reaction at 0 ºC.  The reaction mixture was 
allowed to warm up to 23.0 ºC and refluxed overnight at 80.0 ºC.  The solvent 
  48 
was removed in vacuo to afford a brown residue.  The brown residue was 
dissolved in 150 mL ethyl acetate and extracted with 2N sodium hydroxide.  The 
alkaline extracts were acidified with concentrated hydrochloric acid, extracted 
with ethyl acetate, and removal of the solvent in vacuo to yield 8.15 g of a brown 
oil: 
1
H-NMR (400 MHz, CDCl3) δ 12.20 (br s, 1, 3-OH), 4.07 (br s, 1H, CH), 
3.64 and 3.28 (AB q, 2H, 2-CH2); IR 1654 cm
-1
 (HCO), 1591 cm
-1
 (C=C). 
tert-butyl 3-formyl-1-H-indole-1-carboxylate(9).  Commercially available 1H-
indole-3-carboxaldehyde (10.63 g, 72.23 mmol) was suspended in 200 mL 
benzene at 23.0 ºC. To the aldehyde suspension was added aqueous 30% sodium 
hydroxide (200 mL), Boc anhydride (17.58 g, 80.55 mmol), and 
tetrabutylammonium iodide (2.70 g, 7.32 mmol).  Reaction was stirred vigorously 
for 30 minutes.  At the completion of reaction, the solution was placed in a 
separatory funnel and the organic layer was dried over sodium sulfate.  The 
solvent was removed in vacuo to afford a white solid. 
tert-butyl 3-(hydroxymethyl)-1H-indole-1-carboxylate(10).  To tert-butyl 3-
formyl-1-H-indole-1-carboxylate (17.48 g, 67.5 mmol) in 75.0 mL ethanol was 
added sodium borohydride (2.96 g, 78.4 mmol) slowly at 23.0 ºC.  After 
completion of reaction (monitored by TLC) the solvent was removed in vacuo.  
The solid was extracted with ethyl acetate (3   50.0mL) and brine (3   50.0mL), 
the organic extracts were dried over sodium sulfate, and the solvent was removed 
in vacuo to yield a light yellow solid (16.54 g, 99%): 
1
H-NMR (400 MHz, CDCl3) 
δ 8.15 (d, 1H, Ar), J = 8.1 Hz; 7.64 (d, 1H, Ar), J = 8.0 Hz;  7.57 (s, 1H); 7.34 (t, 
1H), J = 7.1 Hz; 7.26 (t, 1H), J = 7.1 Hz; 4.83 (s, 2H, CH2OH); 1.66 (s, 9H, Boc).           
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tert-butyl 3-(bromomethyl)-1H-indole-1-carboxylate(11).  
To tert-butyl 3-(hydroxymethyl)-1H-indole-1-carboxylate (1.89 g. 7.64 mmol) 
under an argon atmosphere was added 25 mL DCM using a syringe at room 
temperature.  Then a solution of PPh3 (2.20 g, 8.41 mmol) in 20 mL DCM was 
added.  The carbon tetrabromide (2.79 g, 8.41 mmol) was added slowly and the 
reaction stirred at 23.0 ºC for 0.5 h. A deep orange-brown solution was obtained. 
The reaction was rapidly filtered through silica powder and concentrated in vacuo 
to yield a light orange solid (1.73 g,73%): 
1
H-NMR (400 MHz, CDCl3) δ 8.13 (d, 
CH), 7.3-7.7 (m, Ar), 4.67(s, 3CH2), 1.65 (s, t-Bu); 
13
C-NMR (400 MHz, CDCl3) 
δ 24.4, 28.1, 84.1, 115.4, 117.1, 119.3, 122.8, 124.9, 128.7, 149.3. 
tert-butyl 2-((2-oxocyclohexyl)methyl)-1H-indole-1-carboxylate(5).   
Tetrahydrobenzo[b]thiophene-3,4(2H,3aH)-dione (2.03 g, 11.87 mmol) and 
potassium carbonate (1.64 g, 11.87 mmol) was added to refluxing acetone (25 
mL).  To the reaction was added tert-butyl 3-(bromomethyl)-1H-indole-1-
carboxylate (3.68 g, 11.87 mmol) in 10 mL of acetone.  The reaction remained 
under reflux for 2 h and was monitored by TLC. The alkylated product was 
isolated by simple filtration and concentrated in vacuo.  The crude alkylation 
product was added to methanol:water (20 mL).  Ethyl acetate (5 mL) was added 
to the reaction while stirring until complete salvation, followed by addition of 
lithium hydroxide (0.65g, 15.6 mmol).  The solvent was removed in vacuo and 
extracted with ethyl acetate (3   50.0mL) and brine (3   50.0mL), the organic 
extracts were dried over sodium sulfate, and the solvent was removed in vacuo to 
yield a brown oil (4.04 g, 34%): 
1
H-NMR (400 MHz, CDCl3) δ 8.08 (d, 1H, Ar), J 
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= 8.1 Hz; 7.37 (d, 1H, Ar), J = 7.9 Hz;  7.3 (t, 1H); 7.26 (s, 1H); 7.18 (t, 1H); 
6.603 (s, 1H); 3.588 (s, 2H); 2.4 (t, 2H); 1.95 (m, 4H); 1.646 (s, 9H, Boc).           
tert-butyl 2-(((1R,2R)-1,2-dimethyl-6-oxocyclohexyl)methyl)-1H-indole-1-
carboxylate(4a).  Under an argon atmosphere a solution of lithium 
dimethylcuprate in anhydrous diethyl ether (20 mL) was prepared from purified 
copper iodide (2.21 g, 11.62 mmol) in 10 mL diethyl ether and 1.6M methyl 
lithium (14.5 mL, 23.23 mmol) at 0 ºC.  After 15 minutes at 0 ºC, the enone (13 
1.26 g, 3.87 mmol) was added.  The reaction mixture was maintained at 0 ºC for 
1h. To the reaction mixture was added NMP (7.5 mL) followed by rapid addition 
of methyl iodide (2.4 mL, 38.6 mmol).  The reaction was allowed to warm up to 
23.0 ºC and stirred for 3 h. The reaction mixture was poured onto 1.48M 
ammonium hydroxide and the organic layer was extracted with ethyl acetate (3   
50 mL) and washed with brine (3   50 mL), the organic extracts were dried over 
magnesium sulfate, and the solvent was removed in vacuo to yield a dark brown 
oil (1.38 g, 70%): 
1
H-NMR (400 MHz, CDCl3) δ 8.08 (d, 1H, Ar), J = 8.1 Hz; 
7.55 (d, 1H, Ar), J = 7.9 Hz;  7.26 (s, 1H); 7.20 (t, 1H); 7.18 (t, 1H); 3.144,3.179, 
2.792, 2.830 (AB q, 2H); 2.407 (t, 2H); 1.95 (m, 4H); 1.645 (s, 9H, Boc); 1.8 (m, 
2H); 1.68 (m, 1H); 1.44 (m, 1H); 1.069 (s, 3H); 0.965, 0.982 (dd, 3H).            
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Chapter 5 
 
Proposed Completion of Synthesis 
5.1 Future Work 
 The Asymmetric Conjugate Addition (A.C.A.) proved more difficult than 
initially anticipated and therefore progress on the racemic synthesis moved 
forward.  There are a variety of reasons that make copper-catalyzed conjugate 
addition with Grignard reagents problematic; including the presence of competing 
chiral and achiral copper complexes in solution, the sensitivity of reaction 
parameters, and the known deleterious effects of halides on enantioselectivity.
128-
129
  Furthermore, the 1,4-addition with Grignard reagents remains challenging 
because of the possibility of the competing 1,2-addition to the carbonyl group.  
The copper-catalyzed asymmetric conjugate addition of Grignard reagents to 
cyclic enones with enantioselectivities up to 96% was reported in 2004.  The use 
of CuCl over either CuBr or CuBr•SMe2 as the metal source increased the 
regioselectivity (95:5). The use of simple alkylmagnesium bromides as 
nucleophiles and commercially available ferrocenyl diphosphines as chiral ligands 
afforded the best results (Table 5.1).
130
  This work provides the foundation for the 
A.C.A. on the 2-substituted enone 5.  The crucial aspect will be determination of 
the correct ferrocenyl diphosphine ligand . 
Scheme 5.1. Enantioselective Copper-Catalyzed Conjugate Addition of Grignard 
Reagents to Cyclohexenone
130 
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Table 5.1.  Enantioselective Copper-Catalyzed Conjugate Addition of Grignard 
Reagents to Cyclohexenone
130 
Entry
* 
RMgBr Ligand Regio, %
a 
ee 20, % 20 Conf, R/S 
b 
1
c 
EtMgBr 1 95 [69] 96 20a (+)-R 
2 EtMgBr 2 80 10 20a (+)-R 
3 EtMgBr 3 96 94 20a (+)-R 
4 EtMgBr 4 92 93 20a (+)-R 
5 EtMgBr 5 69 45 20a (+)-R 
6
d 
EtMgBr 5 89 40 20a (+)-R 
7
e 
EtMgBr 6 99 56 20a (-)-S 
8
* 
EtMgBr 6 93 30 20a (-)-S 
9 MeMgBr 1 83 90 20b n.d. 
10 PrMgBr 1 81 94 20c n.d. 
11 BuMgBr 1 88 96 20d n.d. 
12
c 
i-PrMgBr 1 78 [72] 1 20e n.d. 
13
c 
i-BuMgBr 1 62 [70] 33 20f (+) 
14
c 
i-Bu(CH2)2MgBr 1 76 [75] 95 20g (+) 
15 Ph(CH2)2MgBr 1 80 77 20h (+)-S 
16 4-Cl-BuMgBr 1 79 85 20i n.d. 
17
e 
i-PrMgBr 6 99 54 20e n.d. 
18
e 
i-BuMgBr 6 99 92 20f (-) 
19
e 
PhMgBr 6 50 40 20j n.d. 
Conf, absolute configuration; n.d.; not determined. 
*More than 98% conversion after 15 min at 0ºC using CuCl. 
a Regioselectivity [9/(9+10)]   100. 
b Absolute configuration and/or sign of optical rotation. 
c Isolated yields are given in brackets. 
d More than 98% conversion after 2 h at -60ºC using CuCl. 
e More than 98% conversion after 2 h at -60ºC using CuBr•SMe2. 
 
 More recently the Feringa group has expanded on the knowledge base of 
catalytic A.C.A. with Grignard reagents and enantioselective copper-catalyzed 
1,4-addition.
121,131
  With increasing interest in the enantioselective 1,4-addition of 
carbon nucleophiles to α,β-unsaturated compounds in which a carbon – carbon 
bond and a new stereogenic center are formed, the ability to use this chemistry on 
the 2-substituted enone 5 will show great progress in this arena.  
 There has been at least one example on the copper-catalyzed A.C.A. of 2-
trisubstituted α,β-unsaturated ketones, however, it involves the use of a 
triorganoaluminum species (R3Al).  Alexakis et al. was able to show trans 1,4- 
addition (trans/cis ratio around 80:20) to 2-methylcyclohex-2-en-1-one using 
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catalytic amounts of copper thiophene carboxylate (CuTC) and binaphthol ligands 
as outlined in table 5.2.
132
  The best results using Me3Al produced enantiomeric 
excess of 90%.  In the present work it will be necessary to determine the 
appropriate ligand necessary for the desired stereochemistry, however, this work 
further supports the ability to use A.C.A. in order to install the enantioselective 
methyl group in the natural product polyalthenol 1. 
Table 5.2. Copper-Catalyzed Asymmetric Conjugate Addition of R3Al to 2-
Methyl-2-Cyclohexenone
132 
 
 
 
Theoretically the second methyl group can be installed using normal 
alkylating conditions with methyl iodide.  Previous work by Boeckman
122
 
supports this addition from the opposite face, which should establish the proper 
relative stereochemistry of the natural product (Scheme 5.2). 
Entry Ligand R3Al (eq.) Adduct Conv. %
a 
ee %
b 
Abs. Conf. 
1 L1 Me3Al (2.0) 23a   95 88 (2S,3R) 
2 L3 Me3Al (2.0) 23a   95 86 (2R,3S) 
3 L4 Me3Al (2.0) 23a   95 80 (2S,3R) 
4 L6 Me3Al (2.0) 23a   95 87 (2R,3S) 
5 L7 Me3Al (2.0) 23a   95 76 (2S,3R) 
6 L8 Me3Al (2.0) 23a   95 90 (2S,3R) 
7 L1 Et3Al (1.4) 23b   95 84 (2S,3R) 
8 L4 Et3Al (1.4) 23b 86 63 (2S,3R) 
9 L8 Et3Al (1.4) 23b   95 (50)
c 93 (2S,3R) 
[a] Conversion determined by GC-MS. 
[b] ee determined by chiral GC. 
[c] Isolated yield. 
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Scheme 5.2.
a
 Enantioselective Methylation 
 
 
 
a
Reagents and conditions: (a) MeMgBr, CuCl (5%), CFDC (6%) or Me3Al, CuTC 
(2%), binaphthol L (4%), Et2O, -30ºC, 18 h; (b) CuI, MeLi, Et2O, 0ºC, 1h 
 
The installation of the final ring of polyalthenol 1 proved more difficult 
than initially anticipated.  The attempts previously made to insert the carbon chain 
necessary for cyclization were unsuccessful and the aldol reaction with acetone, 
upon workup, only showed the presence of starting material.  It was hypothesized 
that the introduction of the final ring could be accomplished using a Robinson 
annulation with mesityl oxide.  This alternative pathway will also insert the 
required geminal dimethyl group.  
A review of literature found at least two instances in which the Robinson 
annulation was performed on hindered ketones.  Jahnke et al. reported the 
successful annulation product of 2-oxocyclohexanecarbonitrile with mesityl 
oxide, albeit with a rather disappointing yield of 16%, accounted for by the steric 
demand of the Michael acceptor.
126  
Dauben initially reported the addition 
products of a variety of cyclic β-keto esters and enone Michael acceptors at high 
pressures (Scheme 5.3).
127
  In the case of five and six member the major products 
(28-30) are bicyclic ketols whereas the product of 2-carbomethoxycycloheptanone 
with mesityl oxide affords the fused ketol (31) as the major product.   
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Scheme 5.3.
a
 Michael Addition Products
127 
 
 
a
Reagents and conditions: (a) 15 kbar, 3:1 CH3CN/base, 20-40ºC 
With the bicyclic ketols (28d-29d) now available and procedures already 
outlined
133-134 
for their conversion to unrearranged bicyclic ketones, it was 
possible to get the desired fused Robinson products (Scheme 5.4) Rearrangement 
catalyzed by hydroxide or alkoxide base proceeds poorly, causing the retro-
Michael reaction, however, it was discovered that treatment of catalytic amounts 
of p-toluenesulfonic acid in benzene with removal of water yields the Robinson 
annulations products (33d-35d). 
Scheme 5.4.
a
 Robinson Annulation Products
127 
 
a
Reagents and conditions: (a) cat. TsOH, C6H6, 80ºC, -H2O 
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Based on the previous works outlined, Robinson annulations on hindered 
ketones with mesityl oxide are possible, and hindered ketone 14a should be no 
exception.  Under the proper conditions, increased pressure and/or heat, the 
Robinson annulation of ketone 14a with mesityl oxide should establish the proper 
ring core of the natural product to afford the annulation product 19 (Scheme 5.5). 
Scheme 5.5.
a
 Synthesis of Ring Core by Robinson Annulation  
 
 
With the Robinson annulation product 19 on hand, the next critical step 
will be a carbonyl transposition out of conjugation in order to set up for the 
subsequent selective reduction and the proper placement of the hydroxyl group 
present in the natural product.  A review of literature identifies vinyl thioethers as 
key intermediates for the 1,2-transposition of ketone groups.
135
  Using this 
approach annulation product 19 can be converted into a sulphonylhydrazone 
derivative using dimethyl disulfide and tosylhydrazone.  This initial derivative 
can be broken down to the key vinylthioether intermediate in the presence of 
excess MeLi.  Hydrolysis in the conventional manner with mercuric chloride 
should afford the transposed ketone 36 (Scheme 5.6).
136 
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Scheme 5.6.
a
 Carbonyl Transposition 
 
 
 
a
Reagents and conditions: (a) i) MeSSMe; ii) TsNHNH2; iii) MeLi (excess); iv) 
HgCl2 
 
 After the completion of the carbonyl transposition, an enantioselective 
reduction of the ketone using a chloroborane reagent is proposed.  The Brown 
reagents di-(isopinocampheyl)chloroborane, (Ipc)2BCl, and di-(iso-2-
ethylapopinocampheyl)chloroborane, (Eap)2BCl, have previously achieved high 
enantioselectivity for aryl and branched dialkyl ketones.
137-138
  Brown et al. 
showed that the reduction of hindered cyclic derivatives is considerably fast, yet 
optical yields are excellent.  For example the reduction of 2,2-
dimethylcyclohexanone 37 with Ipc2BCl 38 yields the corresponding alcohol 39 
in 91% ee (Scheme 5.7).
 
Scheme 5.7.
a
 Reduction of Prochiral Ketones with Ipc2BCl
14
  
 
 
a
Reagents and conditions: (a) 25º C, neat, 12 h 
 
  58 
The use of a Brown’s reagent with ketone 36 should provide the 
enantioselective alcohol 40 that is required by the natural product, with a high 
degree of selectivity (Scheme 5.8).  
 
Scheme 5.8.
a
 Enantioselective Reduction to Alcohol 
 
 
 
The final step in completion of the total synthesis of polyalthenol 1 is the 
removal of the Boc protecting group.  N-Boc deprotection has been successful 
using mild acidic conditions such as trifluoracetic acid (TFA) in 
dichloromethane.
139
  
Scheme 5.9.
a
 Boc Deprotection 
 
 
 
a
Reagents and conditions: (a) TFA, CH2Cl2 
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